Advertisement
Advertisement
Vaxneuvance

Vaxneuvance Dosage/Direction for Use

vaccine, pneumococcal

Manufacturer:

MSD

Distributor:

Zuellig Pharma
Full Prescribing Info
Dosage/Direction for Use
General: The vaccination schedule for VAXNEUVANCE should be based on official recommendations. The national immunization practice recommendations/guidelines should also be considered.
Dosage: Administer a 0.5 mL dose of VAXNEUVANCE intramuscularly.
Method of Administration: For intramuscular use only. Do not inject intravascularly.
The preferred site for injection is the anterolateral aspect of the thigh in infants or the deltoid muscle of the upper arm in children and adults. The vaccine should not be injected in the gluteal area or areas where there may be a major nerve trunk and/or blood vessel.
Pediatrics: Routine Vaccination Schedule for Infants and Toddlers: 4-Dose Regimen (Three-Dose Primary Series Followed by a Toddler Dose): The recommended vaccination regimen consists of 4 doses of VAXNEUVANCE, with the first dose given as early as 6 to 12 weeks of age, with an interval of 4 to 8 weeks between doses in the primary series. The fourth dose should be administered at approximately 11 through 15 months of age and at least 2 months after the third dose.
3-Dose Regimen (Two-Dose Primary Series Followed by a Toddler Dose): The alternative vaccination regimen consists of 3 doses of VAXNEUVANCE, with the first dose given as early as 6 weeks of age, and a second dose administered 8 weeks later. The third dose should be administered at approximately 11 through 15 months of age.
Preterm Infants: Preterm infants (<37 weeks gestation at birth) should receive a 4-dose regimen (three-dose primary series followed by a toddler dose) of VAXNEUVANCE, with the first dose given as early as 6 to 12 weeks of age, with an interval of 4 to 8 weeks between doses in the primary series. The fourth dose should be administered at approximately 11 through 15 months of age and at least 2 months after the third dose. [See Use in Specific Populations under Precautions.]
Prior Vaccination with Another Pneumococcal Conjugate Vaccine: The vaccination regimen can be completed with VAXNEUVANCE if initiated with another pneumococcal conjugate vaccine [see Pharmacology: Pharmacodynamics: Clinical Studies under Actions].
Catch-Up Vaccination Schedule for Children 7 Months Through 17 Years of Age: For children 7 months through 17 years of age who are pneumococcal vaccine-naïve or not fully vaccinated or completed a dosing regimen with lower-valency pneumococcal conjugate vaccines, the following catch-up schedule should be considered: Infants 7 Through 11 months of age: Three doses, with the first two doses given at least 4 weeks apart. The third dose is given after 12 months of age, separated from the second dose by at least 2 months.
Children 12 Through 23 months of age: Two doses, with an interval of 2 months between doses.
Children and adolescents 2 Through 17 years of age: One single dose.
If a previous pneumococcal conjugate vaccine was administered, at least 2 months should elapse before receiving VAXNEUVANCE.
Adults: One single dose.
Special Populations: The dosing schedule in special populations should be guided by official recommendations and may include more than one dose of VAXNEUVANCE [see Use in Specific Populations under Precautions].
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement